title: Novel TGF-βinhibitors ready for prime time in onco-immunology.
abstract: Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees.
authors.affiliation: AFR Oncology, Boulogne-Billancourt , France.
authors.forename: Armand
authors.initials: A
authors.lastname: de Gramont
authors.affiliation: Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Université Paris 7 , Paris, France.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Faivre
authors.affiliation: Medical Oncology, Groupe Hospitalier Paris Saint-Joseph , Paris, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Raymond
keywords: Belagenpumatucel-L; XOMA089; clinical trials; fresolimumab; galunisertib; gemogenovatucel-T; trabedersen